Earlier this week, a small San Diego company named Organovo (ONVO 2.68%) filed its annual report with the SEC. Since then, shares have traded down by as much as 18%.
This appears to be in response to a posting on Seeking Alpha which opined that "Management's obfuscation in its reporting underscores its controversial nature. It undermines management's credibility and lends credence to bears' view that its long-term value proposition of printing human organs is a myth."
While Organovo is often referred to as a company with such a goal, this goal has been thoroughly discussed and is actually a very small part of what the company hopes to accomplish in the near future.
In the slide show below, we'll examine the two big take-aways from the company's report, and whether or not it warrants such a price correction.
